Projo Biz Blog

Alexion's president, David W. Keiser, with Governor Carcieri at a ribbon-cutting ceremony in Smithfield last June.

Leonard Bell, chief executive officer of Alexion Pharmaceuticals Inc. (ALXN:Nasdaq), will speak about the company at the 26th Annual JP Morgan Healthcare Conference in San Francisco on Monday at 7 p.m.

An audio webcast of Bell's remarks will be available live on Alexion's Web site: www.alexionpharm.com.

The biopharmaceutical firm, based in Cheshire, Conn., manufactures the drug Soliris at a contract laboratory in New Hampshire. It plans to shift most of that production to the former Dow Chemical facility in Smithfield, if the FDA certifies the reconstructed plant and approves the quality of the medicine produced there.

Alexion has seen steady revenue growth since it began selling Soliris in the U.S. last April. Shares of its stock closed yesterday at $77.11, up 115 percent from last March, when it traded as low as $35.77.

---